| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 is a BET bromodomain inhibitor that disrupts the interaction between BET proteins and acetylated histones, leading to the inhibition of gene transcription. This indirectly affects SPATA22 regulation. | ||||||
I-BET 151 Hydrochloride | 1300031-49-5 (non HCl Salt) | sc-391115 | 10 mg | $450.00 | 2 | |
I-BET151, like JQ1, is a BET bromodomain inhibitor that disrupts the interaction between BET proteins and acetylated histones, impacting SPATA22 expression through epigenetic regulation. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
Tazemetostat is an EZH2 inhibitor that can potentially affect SPATA22 expression by modulating the epigenetic landscape via inhibition of EZH2. | ||||||
SGC-CBP30 | 1613695-14-9 | sc-473871 sc-473871A | 5 mg 10 mg | $178.00 $338.00 | ||
SGC-CBP30 is a CREB-binding protein (CBP) inhibitor that can impact SPATA22 expression through modulation of CBP's transcriptional co-activator function. | ||||||
CPI-203 | 1446144-04-2 | sc-501599 | 1 mg | $170.00 | ||
CPI-203 inhibits the BET bromodomains, interfering with their role in transcription. This can indirectly affect SPATA22 expression by altering the epigenetic environment. | ||||||
(S)-2-(4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamide | 202590-98-5 | sc-501130 | 2.5 mg | $330.00 | ||
OTX015 is a BET bromodomain inhibitor, impacting SPATA22 expression through its influence on BET proteins and the associated transcriptional machinery. | ||||||
GSK126 | 1346574-57-9 | sc-490133 sc-490133A sc-490133B | 1 mg 5 mg 10 mg | $90.00 $238.00 $300.00 | ||
GSK126 is a BET inhibitor that can disrupt the binding of BET proteins to acetylated histones, indirectly affecting SPATA22 transcription. | ||||||